LCT updates Diabecell trial
Wednesday, 11 February, 2009
Auckland’s Living Cell Technologies (LCT) has reported long-term follow-up results from seven patients implanted with its porcine islet product Diabecell in a Phase I/IIa trial in Russia.
Five patients who received double low-dose implants showed no safety concerns and maintained good blood glucose control. The other two patients on a single higher-dose implant also reported no safety concerns, the company said.
LCT’s medical director Professor Bob Elliott said none of the patients had problems with clinically relevant episodes of low blood glucose.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
